DDInter93 DDInter1008
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is downregulated by {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) regulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is regulated by {v} (Gene) FDFT1
FDFT1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Anagrelide {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Anagrelide may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ketoconazole (Compound)
Anagrelide (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Ketoconazole (Compound)
Anagrelide (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is downregulated by Ketoconazole (Compound)
Anagrelide (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Ketoconazole (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Anagrelide (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) regulates ABHD4 (Gene) and ABHD4 (Gene) is upregulated by Ketoconazole (Compound)
Anagrelide (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is regulated by FDFT1 (Gene) and FDFT1 (Gene) is upregulated by Ketoconazole (Compound)
Anagrelide (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Anagrelide (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Posaconazole (Compound) and Posaconazole (Compound) resembles Ketoconazole (Compound)